Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target at $4.50

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $4.50.

SGMO has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, May 30th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, June 24th. Finally, Barclays dropped their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SGMO. JPMorgan Chase & Co. raised its position in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 25,000 shares during the last quarter. Captrust Financial Advisors bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $30,000. LPL Financial LLC grew its holdings in shares of Sangamo Therapeutics by 113.5% during the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 16,498 shares during the last quarter. Finally, Cerity Partners LLC grew its holdings in shares of Sangamo Therapeutics by 439.2% during the 1st quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 44,800 shares during the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Price Performance

NASDAQ:SGMO traded up $0.03 during mid-day trading on Friday, reaching $0.51. The stock had a trading volume of 5,022,934 shares, compared to its average volume of 9,121,670. The stock has a 50-day simple moving average of $0.50 and a two-hundred day simple moving average of $0.79. The stock has a market capitalization of $118.96 million, a PE ratio of -1.31 and a beta of 1.23. Sangamo Therapeutics has a 12 month low of $0.37 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The company had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative return on equity of 345.98% and a negative net margin of 124.61%. Equities analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.